DK3792628T3 - Fremgangsmåder til forudsigelse af neoantigeners anvendelighed til immunterapi - Google Patents
Fremgangsmåder til forudsigelse af neoantigeners anvendelighed til immunterapi Download PDFInfo
- Publication number
- DK3792628T3 DK3792628T3 DK20193183.9T DK20193183T DK3792628T3 DK 3792628 T3 DK3792628 T3 DK 3792628T3 DK 20193183 T DK20193183 T DK 20193183T DK 3792628 T3 DK3792628 T3 DK 3792628T3
- Authority
- DK
- Denmark
- Prior art keywords
- neoantigens
- predicting
- usefulness
- methods
- immune therapy
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/060897 WO2017194170A1 (en) | 2016-05-13 | 2016-05-13 | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
| EP17726208.6A EP3455625B1 (en) | 2016-05-13 | 2017-05-10 | Methods for predicting the usefulness of neoantigens for immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3792628T3 true DK3792628T3 (da) | 2024-06-17 |
Family
ID=55971007
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20193183.9T DK3792628T3 (da) | 2016-05-13 | 2017-05-10 | Fremgangsmåder til forudsigelse af neoantigeners anvendelighed til immunterapi |
| DK17726208.6T DK3455625T3 (da) | 2016-05-13 | 2017-05-10 | Fremgangsmåder til forudsigelse af anvendeligheden af neo-antigener til immunterapi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17726208.6T DK3455625T3 (da) | 2016-05-13 | 2017-05-10 | Fremgangsmåder til forudsigelse af anvendeligheden af neo-antigener til immunterapi |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US12153041B2 (https=) |
| EP (3) | EP4411376A3 (https=) |
| JP (5) | JP7529381B2 (https=) |
| KR (3) | KR20220020993A (https=) |
| CN (1) | CN109073637A (https=) |
| AU (2) | AU2017264546B2 (https=) |
| BR (1) | BR112018073221A2 (https=) |
| CA (1) | CA3022654A1 (https=) |
| CY (1) | CY1123520T1 (https=) |
| DK (2) | DK3792628T3 (https=) |
| ES (2) | ES2826480T3 (https=) |
| FI (1) | FI3792628T3 (https=) |
| HR (2) | HRP20240704T1 (https=) |
| HU (2) | HUE067497T2 (https=) |
| IL (2) | IL300841A (https=) |
| LT (2) | LT3455625T (https=) |
| MA (1) | MA43794B1 (https=) |
| MD (1) | MD3455625T2 (https=) |
| MX (2) | MX393653B (https=) |
| PL (2) | PL3455625T3 (https=) |
| PT (2) | PT3792628T (https=) |
| RS (2) | RS65568B1 (https=) |
| SG (1) | SG11201808495SA (https=) |
| SI (2) | SI3792628T1 (https=) |
| SM (2) | SMT202400232T1 (https=) |
| WO (2) | WO2017194170A1 (https=) |
| ZA (1) | ZA201805809B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL260030B2 (en) | 2016-01-08 | 2025-12-01 | Nykode Therapeutics ASA | Therapeutic anticancer neoepitope vaccine |
| WO2017194170A1 (en) | 2016-05-13 | 2017-11-16 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
| EP3933408A1 (en) | 2017-05-30 | 2022-01-05 | Nant Holdings IP LLC | Circulating tumor cell enrichment using neoepitopes |
| JP6857930B2 (ja) * | 2018-02-15 | 2021-04-14 | 国立大学法人旭川医科大学 | がん抗原ペプチド |
| CA3106564A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| US20220349010A1 (en) | 2018-07-26 | 2022-11-03 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
| CN109021062B (zh) * | 2018-08-06 | 2021-08-20 | 倍而达药业（苏州）有限公司 | 一种肿瘤新抗原的筛选方法 |
| CN111621564B (zh) * | 2019-02-28 | 2022-03-25 | 武汉大学 | 一种鉴定有效肿瘤新抗原的方法 |
| TWI894138B (zh) * | 2019-03-06 | 2025-08-21 | 美商西雅圖項目公司 | 利用ii 類mhc 模型鑑別新抗原 |
| CN110534156B (zh) * | 2019-09-02 | 2022-06-17 | 深圳市新合生物医疗科技有限公司 | 一种提取免疫治疗新抗原的方法及系统 |
| CN111487399B (zh) * | 2020-03-26 | 2021-09-17 | 湖南师范大学 | 一种蛋白分子标记在鱼类生殖细胞发育研究中的应用 |
| WO2023025404A1 (en) | 2021-08-24 | 2023-03-02 | BioNTech SE | In vitro transcription technologies |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2766205B1 (fr) * | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| DK1276896T3 (da) * | 2000-04-28 | 2010-10-18 | Mannkind Corp | Epitop-synkronisering i antigen-præsenterende celler |
| CA2415902A1 (en) | 2000-07-10 | 2002-01-17 | Xencor | Protein design automation for designing protein libraries with altered immunogenicity |
| JP4900884B2 (ja) * | 2000-07-31 | 2012-03-21 | 株式会社グリーンペプタイド | 腫瘍抗原 |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| TW200413539A (en) * | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Genes and polypeptides relating to prostate cancers |
| WO2006105255A2 (en) * | 2005-03-29 | 2006-10-05 | The Board Of Trustees Of The University Of Illinois | Cancer vaccines and therapeutic methods |
| JP2009273377A (ja) * | 2008-05-12 | 2009-11-26 | Igaku Seibutsugaku Kenkyusho:Kk | Ｍｈｃクラスｉ分子と結合し癌細胞の表面に表出されるペプチド候補の選択方法 |
| TW201000119A (en) * | 2008-06-10 | 2010-01-01 | Oncotherapy Science Inc | MYBL2 epitope peptides and vaccines containing the same |
| RS53782B1 (sr) * | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| CA2755983A1 (en) | 2009-03-23 | 2010-09-30 | The Walter And Eliza Hall Institute Of Medical Research | Compounds and methods for modulating an immune response |
| AU2010310468A1 (en) * | 2009-10-23 | 2012-05-24 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| PL3892295T3 (pl) | 2011-05-24 | 2023-07-24 | BioNTech SE | Zindywidualizowane szczepionki przeciwnowotworowe |
| WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| EP2714730A1 (en) * | 2011-06-01 | 2014-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel antigen peptide and uses thereof |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| ES2970865T3 (es) | 2015-12-16 | 2024-05-31 | Gritstone Bio Inc | Identificación, fabricación y uso de neoantígenos |
| WO2017194170A1 (en) | 2016-05-13 | 2017-11-16 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
| CA3060569A1 (en) | 2017-04-19 | 2018-10-25 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
| AU2018279627B2 (en) | 2017-06-09 | 2023-08-10 | Seattle Project Corp. | Neoantigen identification, manufacture, and use |
| US20200363414A1 (en) | 2017-09-05 | 2020-11-19 | Gritstone Oncology, Inc. | Neoantigen Identification for T-Cell Therapy |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
| EP3759131A4 (en) | 2018-02-27 | 2021-12-01 | Gritstone bio, Inc. | NEOANTIGEN IDENTIFICATION WITH PAN ALLELE MODELS |
-
2016
- 2016-05-13 WO PCT/EP2016/060897 patent/WO2017194170A1/en not_active Ceased
-
2017
- 2017-05-10 EP EP24171718.0A patent/EP4411376A3/en active Pending
- 2017-05-10 HU HUE20193183A patent/HUE067497T2/hu unknown
- 2017-05-10 MA MA43794A patent/MA43794B1/fr unknown
- 2017-05-10 MD MDE20190332T patent/MD3455625T2/ro unknown
- 2017-05-10 PT PT201931839T patent/PT3792628T/pt unknown
- 2017-05-10 MX MX2018013081A patent/MX393653B/es unknown
- 2017-05-10 BR BR112018073221-4A patent/BR112018073221A2/pt unknown
- 2017-05-10 JP JP2018559794A patent/JP7529381B2/ja active Active
- 2017-05-10 WO PCT/EP2017/061196 patent/WO2017194610A1/en not_active Ceased
- 2017-05-10 HU HUE17726208A patent/HUE052240T2/hu unknown
- 2017-05-10 LT LTEP17726208.6T patent/LT3455625T/lt unknown
- 2017-05-10 HR HRP20240704TT patent/HRP20240704T1/hr unknown
- 2017-05-10 FI FIEP20193183.9T patent/FI3792628T3/fi active
- 2017-05-10 ES ES17726208T patent/ES2826480T3/es active Active
- 2017-05-10 KR KR1020227002915A patent/KR20220020993A/ko not_active Ceased
- 2017-05-10 EP EP17726208.6A patent/EP3455625B1/en active Active
- 2017-05-10 AU AU2017264546A patent/AU2017264546B2/en active Active
- 2017-05-10 SG SG11201808495SA patent/SG11201808495SA/en unknown
- 2017-05-10 RS RS20240614A patent/RS65568B1/sr unknown
- 2017-05-10 US US16/301,019 patent/US12153041B2/en active Active
- 2017-05-10 PT PT177262086T patent/PT3455625T/pt unknown
- 2017-05-10 CN CN201780026579.0A patent/CN109073637A/zh active Pending
- 2017-05-10 DK DK20193183.9T patent/DK3792628T3/da active
- 2017-05-10 HR HRP20201671TT patent/HRP20201671T1/hr unknown
- 2017-05-10 SM SM20240232T patent/SMT202400232T1/it unknown
- 2017-05-10 IL IL300841A patent/IL300841A/en unknown
- 2017-05-10 PL PL17726208T patent/PL3455625T3/pl unknown
- 2017-05-10 KR KR1020187032652A patent/KR102358620B1/ko active Active
- 2017-05-10 RS RS20201233A patent/RS61071B1/sr unknown
- 2017-05-10 DK DK17726208.6T patent/DK3455625T3/da active
- 2017-05-10 ES ES20193183T patent/ES2980781T3/es active Active
- 2017-05-10 PL PL20193183.9T patent/PL3792628T3/pl unknown
- 2017-05-10 SI SI201731526T patent/SI3792628T1/sl unknown
- 2017-05-10 EP EP20193183.9A patent/EP3792628B1/en active Active
- 2017-05-10 LT LTEP20193183.9T patent/LT3792628T/lt unknown
- 2017-05-10 SI SI201730466T patent/SI3455625T1/sl unknown
- 2017-05-10 CA CA3022654A patent/CA3022654A1/en active Pending
- 2017-05-10 KR KR1020247031632A patent/KR20240146087A/ko active Pending
- 2017-05-10 SM SM20200622T patent/SMT202000622T1/it unknown
-
2018
- 2018-08-29 ZA ZA2018/05809A patent/ZA201805809B/en unknown
- 2018-10-25 MX MX2022007902A patent/MX2022007902A/es unknown
- 2018-10-29 IL IL262680A patent/IL262680B2/en unknown
-
2020
- 2020-10-14 CY CY20201100969T patent/CY1123520T1/el unknown
-
2022
- 2022-02-16 JP JP2022021751A patent/JP2022081492A/ja active Pending
- 2022-07-27 AU AU2022209286A patent/AU2022209286A1/en active Pending
-
2024
- 2024-03-21 JP JP2024045130A patent/JP2024096712A/ja active Pending
- 2024-04-23 JP JP2024069742A patent/JP2024112805A/ja active Pending
- 2024-06-27 JP JP2024103724A patent/JP2024160216A/ja active Pending
- 2024-10-18 US US18/920,525 patent/US20250244311A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3792628T3 (da) | Fremgangsmåder til forudsigelse af neoantigeners anvendelighed til immunterapi | |
| CY2025001I1 (el) | Νεα αντι-pd-l1 αντισωματα | |
| IL299926A (en) | Neoantigens and methods of their use | |
| IL255769A (en) | Shared neoantigens | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
| DK3253865T3 (da) | Fremgangsmåder til forbedring af virkningen af terapeutiske immunceller | |
| DK3563156T3 (da) | Fremgangsmåde til separering af biomolekyler | |
| DK3331915T3 (da) | Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere | |
| DK3185854T3 (da) | Injicerbare opslæmninger og fremgangsmåder til fremstilling og anvendelse af disse | |
| DK3221346T3 (da) | Antistoffer omfattende modificerede konstante områder af tungkæden | |
| DK3110440T5 (da) | Anti-cd38-antistoffer til behandling af akut lymfatisk leukæmi | |
| DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
| DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3452507T3 (da) | Tau-immunoterapi | |
| DK3128910T3 (da) | Fremgangsmåde til bestemmelse af tværsnitsarealet og voluminet af et objekt | |
| DK3218396T3 (da) | Fremgangsmåde til fremstilling af højaffinitets antistoffer | |
| DK3551629T3 (da) | Oxabicycloheptaner til modulering af immunrespons | |
| DK3224356T3 (da) | Metoder til rekombinant udtrykkelse af beta-glucosidase-gen | |
| DK3484921T3 (da) | Anti-IL-22R antistoffer | |
| DK3452515T3 (da) | Her-2-bindende antistoffer | |
| DK3107554T3 (da) | Antistof til påvirkning af kønsforholdet og metoder til anvendelse deraf | |
| HUE062670T2 (hu) | Eljárás földimogyoró-antigéneket tartalmazó készítmények jellemzésére | |
| DK3748358T3 (da) | Cellebaseret fremgangsmåde til bestemmelse af virkningsgraden af defibrotid | |
| DK3438280T3 (da) | Fremgangsmåde til påvisning af hæmoplasma |